New Hope for Depression Patients
New Hope for Depression Patients
Half of People With Major Depression Get Well After 1st or 2nd Treatment
March 22, 2006 -- Don't give up hope, a new study suggests to people suffering with depression.
It may take 14 weeks and a change of medication, but people with major depression now have a 50-50 chance of getting better and getting well.
What about the 50% of people who don't get well? There's still hope they'll get well, too.
The findings come from the second phase of the STAR-D trial. It's an ambitious, ongoing study funded by the National Institute of Mental Health. The goal: to see, in a step-by-step fashion, just what it takes to put major depression into full remission.
Phase I of the trialPhase I of the trial showed that he antidepressantCelexa helps nearly a third of patients get well. Now phase II of the trial shows that switching drugs or adding a new drug makes a third of the remaining patients well.
That adds up to about half of the patients in the study, says study co-leader A. John Rush, MD, professor and vice chairman for research in psychiatry at the University of Texas Southwestern Medical Center at Dallas.
"The big message is that symptoms can be eliminated in over 50% of people who receive two treatment steps," Rush said at a news conference. "For patients, it is important not to give up if the first treatment does not work fully, or if it causes side effects. ... Most patients should expect at least two treatment attempts to become asymptomatic."
Results of the $35 million study -- funded by the NIMH and not by drug companies -- appear in two papers in the March 23 issue of The New England Journal of Medicine.
The size of this government effort to find effective depression treatments testifies to the severity of the illness. Depression is often seen "as a weakness, if not a vice," notes an NEJM editorial by David R. Rubinow, MD, chairman of psychiatry at the University of North Carolina at Chapel Hill.
"The STAR-D trial is attempting to discover the best way of treating a destructive, malignant, and life-threatening illness," Rubinow tells WebMD. "Anything that can help reduce the astronomical burden of depression is well worth the investment of public resources."
New Hope for Depression Patients
Half of People With Major Depression Get Well After 1st or 2nd Treatment
March 22, 2006 -- Don't give up hope, a new study suggests to people suffering with depression.
It may take 14 weeks and a change of medication, but people with major depression now have a 50-50 chance of getting better and getting well.
What about the 50% of people who don't get well? There's still hope they'll get well, too.
The findings come from the second phase of the STAR-D trial. It's an ambitious, ongoing study funded by the National Institute of Mental Health. The goal: to see, in a step-by-step fashion, just what it takes to put major depression into full remission.
Phase I of the trialPhase I of the trial showed that he antidepressantCelexa helps nearly a third of patients get well. Now phase II of the trial shows that switching drugs or adding a new drug makes a third of the remaining patients well.
That adds up to about half of the patients in the study, says study co-leader A. John Rush, MD, professor and vice chairman for research in psychiatry at the University of Texas Southwestern Medical Center at Dallas.
"The big message is that symptoms can be eliminated in over 50% of people who receive two treatment steps," Rush said at a news conference. "For patients, it is important not to give up if the first treatment does not work fully, or if it causes side effects. ... Most patients should expect at least two treatment attempts to become asymptomatic."
Results of the $35 million study -- funded by the NIMH and not by drug companies -- appear in two papers in the March 23 issue of The New England Journal of Medicine.
Depression: An Emotional Cancer
The size of this government effort to find effective depression treatments testifies to the severity of the illness. Depression is often seen "as a weakness, if not a vice," notes an NEJM editorial by David R. Rubinow, MD, chairman of psychiatry at the University of North Carolina at Chapel Hill.
"The STAR-D trial is attempting to discover the best way of treating a destructive, malignant, and life-threatening illness," Rubinow tells WebMD. "Anything that can help reduce the astronomical burden of depression is well worth the investment of public resources."
Source...